Figure 3
Atherogenic-dyslipidaemic biomarkers. Relative risk ratio for each illness phenotype, per 1-SD increase in biomarker. Adjusted for age, sex and body mass index. 95% Confidence intervals displayed with P-values adjusted using Benajmini-Hochberg False Discovery Rate correction. Red indicates FDR corrected P-value ≤ 0.05. ACI: Acute COVID-19 illness, OSC28: Ongoing symptomatic COVID-19 (28–83 days), PCS84: Post COVID-19 syndrome (≥ 84 days), NC28: Non-COVID-19 illness 28–83 days, NC84: Non-COVID-19 illness ≥ 84 days, ApoB_by_ApoA1: Ratio of apolipoprotein B to apolipoprotein A1, HDL_C: High density lipoprotein cholesterol, HDL_L: Total Lipids in high density lipoprotein, LDL_TG: Triglycerides in low density Lipoprotein, L_HDL_P: Concentration of large high density lipoprotein particles, MUFA: Monounsaturated Fatty Acids, PUFA_by_MUFA: Ratio of polyunsaturated fatty acids to monounsaturated fatty acids, Remnant_C: Remnant cholesterol (non-HDL, non-LDL -cholesterol), S_HDL_TG: Cholesterol in small HDL, VLDL_C: Very low density lipoprotein cholesterol, VLDL_L: Total lipids in VLDL, VLDL_TG: Triglycerides in VLDL, VLDL_size: Average diameter for VLDL particles.
